Naloxegol

Revision as of 17:01, 9 April 2015 by Rabin Bista (talk | contribs) (Created page with "{{Drugbox | IUPAC_name = (5α,6α)-17-Allyl-6-[(20-hydroxy-3,6,9,12,15,18-hexaoxaicos-1-yl)oxy]-4,5-epoxymorphinan-3,14-diol | image = Naloxegol.svg | width = | image2 = |...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Naloxegol
File:Naloxegol.svg
Clinical data
Trade namesMovantik
AHFS/Drugs.commovantik
[[Regulation of therapeutic goods |Template:Engvar data]]
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • US: Unscheduled
Pharmacokinetic data
Protein binding~4.2%
MetabolismHepatic (CYP3A)
Elimination half-life6–11 h
ExcretionFeces (68%), urine (16%)
Identifiers
CAS Number
PubChem CID
ChemSpider
ChEBI
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC34H53NO11
Molar mass651.785
3D model (JSmol)

Naloxegol (INN; NKTR-118), or PEGylated naloxol,[1] trade name Movantik, is a peripherally-selective opioid antagonist under development by AstraZeneca, licensed from Nektar, for the treatment of opioid-induced constipation.[2]

See also

References

  1. Roland Seifert; Thomas Wieland; Raimund Mannhold (17 July 2006). G Protein-Coupled Receptors as Drug Targets: Analysis of Activation and Constitutive Activity. John Wiley & Sons. p. 227. ISBN 978-3-527-60695-5. Retrieved 14 May 2012. Unknown parameter |coauthors= ignored (help)
  2. "Nektar | R&D Pipeline | Products in Development | CNS/Pain | Oral Naloxegol (NKTR-118) and Oral NKTR-119". Retrieved 2012-05-14.

Template:Laxatives


Template:Nervous-system-drug-stub